Abstract
Cardiac amyloidosis (CA) is a devastating disorder due to deposition of amyloid protein fibrils (light chains in AL or transthyretin in ATTR) in extracellular tissue. Untreated, CA has a life expectancy of approximately 4 years. Disease modifying treatments are now available; however, they are based on the underlying subtype. Despite improved non-invasive diagnostic tools, mass spectrometry (MS) of endomyocardial tissue is essential for cases with a mixed sub-type.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
